Orbimed Advisors LLC Shattuck Labs, Inc. Transaction History
Orbimed Advisors LLC
- $2.93 Billion
- Q3 2025
A detailed history of Orbimed Advisors LLC transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,306,127 shares of STTK stock, worth $12.4 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
6,306,127Holding current value
$12.4 Million% of portfolio
0.5%Shares
1 transactions
Others Institutions Holding STTK
# of Institutions
60Shares Held
38.5MCall Options Held
22.2KPut Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA6.31MShares$12.4 Million0.02% of portfolio
-
Redmile Group, LLC San Francisco, CA5.54MShares$10.9 Million1.42% of portfolio
-
Prosight Management, LP Dallas, TX5.45MShares$10.7 Million3.36% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$4.85 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.13MShares$4.17 Million0.0% of portfolio
About Shattuck Labs, Inc.
- Ticker STTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,382,000
- Market Cap $83.1M
- Description
- Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...